Licofelone

DB04725ExperimentalSmall molecule

Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new... It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis.

Mechanism: Licofelone, through combined 5-LOX/COX-inhibition, reduces levels of inflammatory prostaglandins and leukotrienes.
Curator reviewed
Primary indication: For the management of osteoarthritis.Curator reviewed
Formula / weight: C₂₃H₂₂ClNO₂ · 379.879 g/mol (avg)
Code names: ML-3000

Resolves to

Compound

UNIIP5T6BYS22YCAS156897-06-2ChEMBLCHEMBL300982ChEBI47532PubChem133021

Structure

InChIKeyUAWXGRJVZSAUSZ-UHFFFAOYSA-NSMILESCC1(C)CN2C(CC(O)=O)=C(C(=C2C1)C1=CC=CC=C1)C1=CC=C(Cl)C=C1

Targets

P09917ALOX5P35354PTGS2Q9NZK7PLA2G2E

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

978Drug interactionsStructured to mechanism, not free text

16+ReferencesStructured and connected to the statements they support

Which drugs share a target with Licofelone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account